Head & Neck Oncology Department, Gustave Roussy Cancer Campus, Grand Paris, France.
Department of Biostatistics, Gustave Roussy Cancer Campus, Grand Paris, France.
Oral Oncol. 2018 Jul;82:187-194. doi: 10.1016/j.oraloncology.2018.05.021. Epub 2018 Jun 6.
Evaluate the reliability of sentinel node biopsy (SNB) in T1/T2 cN0 oral squamous cell carcinoma (OSCC), and compare recurrence-free time (RFT) and overall survival (OS) between patients undergoing SNB and neck dissection (ND).
Patients with T1/T2 cN0 OSCC underwent SNB followed by systematic ND in the first cohort and SNB followed by selective ND in case of positive sentinel nodes (SN) in the second cohort.
A total of 229 patients were followed (first cohort 50, second cohort 179). SNs were successfully detected in 93.9% (215/229) of cases. Median follow-up was 5.6 years. Recurrence occurred in 38/215 patients, with isolated nodal recurrence in 18/215 patients. At 5 years, the rate of recurrence-free patients was 80.0% and the rate of patients without isolated nodal recurrence was 90.4%. Negative predictive value of SNB was 92.7%. No statistically significant difference was observed between the two groups regarding RFT and OS. In 83% (10/12) of ipsilateral isolated nodal recurrences, primary tumor was located in anterior part of oral cavity. Only 43% (3/7) of SN+ patients with nodal recurrence were eligible for salvage surgery, compared to 91% (10/11) of SN- patients. SNB resulted in fewer complications than ND (8% vs 28%, p < 0.0001).
SNB is a reliable staging tool for T1/T2 cN0 OSCC, without adverse effect on patient survival and fewer complications. No late recurrences occurred in long-term follow-up. Close follow-up is mandatory for SN+ patients, who are at higher risk of nodal recurrence and have worse prognosis.
评估 T1/T2 cN0 口腔鳞状细胞癌(OSCC)前哨淋巴结活检(SNB)的可靠性,并比较 SNB 与颈淋巴结清扫术(ND)治疗 T1/T2 cN0 OSCC 患者的无复发生存时间(RFT)和总生存(OS)。
第一队列中 T1/T2 cN0 OSCC 患者接受 SNB 后行系统 ND,第二队列中 SNB 后若 SN 阳性则行选择性 ND。
共 229 例患者接受随访(第一队列 50 例,第二队列 179 例)。93.9%(215/229)的病例成功检测到 SNs。中位随访时间为 5.6 年。215 例患者中有 38 例复发,18 例为孤立淋巴结复发。5 年时无复发生存率为 80.0%,无孤立淋巴结复发率为 90.4%。SNB 的阴性预测值为 92.7%。两组患者 RFT 和 OS 无统计学差异。同侧孤立淋巴结复发的 83%(10/12)患者,原发肿瘤位于口腔前部分。只有 43%(3/7)的淋巴结复发 SN+患者适合挽救性手术,而 SN-患者为 91%(10/11)。SNB 导致的并发症少于 ND(8% vs 28%,p<0.0001)。
SNB 是 T1/T2 cN0 OSCC 的一种可靠分期工具,对患者的生存无不良影响,并发症更少。长期随访无迟发复发。SN+患者淋巴结复发风险较高,预后较差,需密切随访。